CeriBell (NASDAQ:CBLL – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($1.03), Zacks reports. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million.
CeriBell Stock Performance
Shares of NASDAQ CBLL traded up $0.64 during mid-day trading on Thursday, hitting $28.52. 23,296 shares of the stock traded hands, compared to its average volume of 227,971. CeriBell has a 52 week low of $23.00 and a 52 week high of $29.53.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on CBLL. William Blair started coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target for the company. Canaccord Genuity Group initiated coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price for the company. Bank of America started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Canaccord Genuity Group lifted their target price on shares of CeriBell from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $31.20.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
- Five stocks we like better than CeriBell
- What is Put Option Volume?
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- 5 discounted opportunities for dividend growth investors
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
